Dalfampridine IR is under clinical development by Solaxa and currently in Phase II for Spinocerebellar Ataxia (SCA). According to GlobalData, Phase II drugs for Spinocerebellar Ataxia (SCA) have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dalfampridine IR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dalfampridine IR overview
Dalfampridine is under development for the treatment of spinocerebellar ataxia -27B (SCA27B). The drug candidate is administered through oral route. It acts by targeting voltage gated potassium channel.
Solaxa overview
Solaxa focused on research, developing and marketing of neuro-regenerative therapies for the treatment of nerve damage. The company is headquartered in Montgomery, Maryland, the US.
For a complete picture of Dalfampridine IR’s drug-specific PTSR and LoA scores,
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData鈥檚 unrivalled proprietary data will enable you to decode what鈥檚 happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
